Search Results for "golimumab"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for golimumab. Results 11 to 19 of 19 total matches.
See also: Simponi

Table: Some Drug Interactions with Drugs for IBD (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
, adalimumab, golimumab, certolizumab pegol. Table: Some Drug Interactions with Drugs for IBD sulfasalazine ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114   doi:10.58347/tml.2023.1680c |  Show IntroductionHide Introduction

Tofacitinib (Xeljanz) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2013  (Issue 1407)
Golimumab – Simponi (Janssen) 50 mg/0.5 mL syringe 50 mg SC once/month 2218.84 Infliximab – Remicade ...
The FDA has approved tofacitinib (toe” fa sye’ ti nib; Xeljanz – Pfizer), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to or are intolerant of methotrexate. Ruxolitinib (Jakafi) is the only other JAK inhibitor available in the US; it is FDA-approved for treatment of myelofibrosis.
Med Lett Drugs Ther. 2013 Jan 7;55(1407):1-3 |  Show IntroductionHide Introduction

Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
), golimumab (Simponi), or infliximab (Remicade, and biosimilars), the integrin receptor antagonist ...
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors. Upadacitinib is the second JAK inhibitor to be approved for this indication; tofacitinib (Xeljanz) was the first. Upadacitinib is also approved for treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):142-4 |  Show IntroductionHide Introduction

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
, single-use pens at week 2 Maintenance: 40 mg SC every other week starting at week 4 Golimumab ...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) are FDA ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Sarilumab (Kevzara) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017  (Issue 1527)
. Cimzia coticosteroids Enbrel Erelzi etanercept golimumab certolizumab Brenzys biosimilars anakinra ...
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6 inhibitor to be approved for this indication; tocilizumab (Actemra) was approved earlier.
Med Lett Drugs Ther. 2017 Aug 14;59(1527):134-6 |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
, and biosimilars), adalimumab (Humira, and biosimilars), and golimumab (Simponi) are FDA-approved for use ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Drugs for Tuberculosis

   
Treatment Guidelines from The Medical Letter • Apr 01, 2012  (Issue 116)
), etanercept (Enbrel), adalimumab (Humira), certolizumab pegol (Cimzia) or golimumab (Simponi) are at high ...
Tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses challenges to its treatment and control. Guidelines with detailed management recommendations are available from the American Thoracic Society, Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA).
Treat Guidel Med Lett. 2012 Apr;10(116):29-36 |  Show IntroductionHide Introduction

Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
Renflexis Remicade infliximab Simponi golimumab certolizumab Amjevita adalimumab TNF inhibitors Cortifoam ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9   doi:10.58347/tml.2023.1680d |  Show IntroductionHide Introduction